{"title":"Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1810","DOIUrl":null,"url":null,"abstract":"Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy. The deal follows the successful completion by Vascular Pharma of a US$16 M Series A equity financing, the company’s first institutional round of funding, which it hopes will be sufficient to advance preclinical-stage VPI-2690B through Phase II.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I9.1810","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy. The deal follows the successful completion by Vascular Pharma of a US$16 M Series A equity financing, the company’s first institutional round of funding, which it hopes will be sufficient to advance preclinical-stage VPI-2690B through Phase II.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
